Market Research Logo

Japan Market Report for Interventional Coronary Catheters 2018 - MedCore

EXECUTIVE SUMMARY
JAPAN INTERVENTIONAL CARDIOLOGY MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
MARKETS INCLUDED
PROCEDURES INCLUDED
VERSION HISTORY
RESEARCH METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecasts and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
DISEASE OVERVIEW
2.1 BASIC ANATOMY
2.2 DISEASE TREATMENTS AND DIAGNOSTICS
2.2.1 General Diagnostics
2.2.2 Coronary Artery Disease (CAD)
2.2.3 Myocardial Infarction (MI)
2.2.4 Angina Pectoris
2.3 PATIENT DEMOGRAPHICS
2.3.1 General Statistics
PRODUCT ASSESSMENT
3.1 PRODUCT PORTFOLIOS
3.1.1 Coronary Catheters Market
3.1.1.1 Diagnostic Coronary Catheter
3.1.1.2 Interventional Coronary Catheters
3.1.1.3 Intravascular Ultrasound (IVUS) Catheter
3.1.1.4 Optical Coherence Tomography (OCT) Catheter
3.2 REGULATORY ISSUES AND RECALLS
3.2.1 Boston Scientific
3.2.1.1 Coronary Stent
3.2.1.2 PTCA Balloon Catheter
3.2.1.3 Interventional Coronary Catheters and Guidewires
3.2.1.4 Coronary Embolic Protection Device
3.2.2 Cardinal Health
3.2.2.1 Coronary Vascular Closure Device
3.2.3 Cook Medical
3.2.3.1 Coronary Stent
3.2.3.2 Interventional Coronary Catheters and Guidewires
3.2.4 Cordis (Cardinal Health)
3.2.4.1 PTCA Balloon Catheter/Dilation Catheters
3.2.4.2 Interventional Coronary Catheters and Guidewires
3.2.5 Medtronic
3.2.5.1 Coronary Stent
3.2.5.2 PTCA Balloon and Dilation Catheters
3.2.5.3 Interventional Coronary Catheters and Guidewires
3.2.6 Merit Medical Systems
3.2.6.1 Interventional Coronary Catheters and Guidewires
3.2.6.2 Coronary Introducer Sheath
3.2.7 Spectranetics
3.2.7.1 Coronary Atherectomy Device
3.2.8 St. Jude Medical (Abbott Laboratories)
3.2.8.1 Coronary Vascular Closure Device
3.2.8.2 Interventional Coronary Catheters and Guidewires
3.2.9 Vascular Solutions (Teleflex)
3.2.9.1 Interventional Coronary Catheters and Guidewires
3.2.10 Volcano Therapeutics (Philips Volcano)
3.2.10.1 Interventional Coronary Catheters and Guidewires
3.2.10.2 Intravascular Ultrasound (IVUS) Catheter
3.2.11 Other Companies
3.2.11.1 Coronary Stent and other Vascular Stents
3.2.11.2 PTCA balloon catheter
3.2.11.3 Interventional Coronary Catheters and Guidewires
3.2.11.4 Coronary Atherectomy Device
3.2.11.5 Coronary Introducer Sheath
3.2.11.6 Intravascular Ultrasound (IVUS) Catheter
3.3 CLINICAL TRIALS
3.3.1 Abbott Laboratories
3.3.1.1 Coronary Stent
3.3.2 Asahi Intecc
3.3.2.1 Interventional Coronary Catheters and Guidewires
3.3.3 B. Braun
3.3.3.1 Coronary Stent
3.3.3.2 PTCA balloon catheter
3.3.4 Biosensors
3.3.4.1 Coronary Stent
3.3.5 Biotronik
3.3.5.1 Coronary Stent
3.3.5.2 PTCA balloon catheter
3.3.6 Boston Scientific
3.3.6.1 Coronary Stent
3.3.6.3 PTCA balloon catheter
3.3.6.4 Coronary Embolic Protection Device
3.3.7 Medtronic
3.3.7.1 Coronary Stent
3.3.7.2 Interventional Coronary Catheters and Guidewires
3.3.7.3 Coronary Embolic Protection Device
3.3.8 St. Jude Medical (Abbott Laboratories)
3.3.8.1 Interventional Coronary Catheters and Guidewires
3.3.8.2 Intravascular Ultrasound (IVUS) Catheter
3.3.8.3 Optical Coherence Tomography Catheter
3.3.8.4 Fractional Flow Reverse (FFR) Catheter
3.3.9 Terumo Interventional Systems (TIS)
3.3.9.1 Interventional Coronary Catheters and Guidewires
3.3.9.2 Coronary Embolic Protection Device
3.3.10 Other Companies
3.3.10.1 Coronary Stent
3.3.10.2 PTCA balloon catheter
3.3.10.3 Interventional Coronary Catheters and Guidewires
3.3.10.4 Coronary Embolic Protection Device
3.3.10.5 Coronary Chronic Total Occlusion Crosser CTO
3.3.10.7 Fractional Flow Reserve (FFR) Guidewire
3.3.10.8 Optical Coherence Tomography (OCT) Guidewire
INTERVENTIONAL CORONARY CATHETER MARKET
4.1 INTRODUCTION
4.2 MARKET ANALYSIS AND FORECAST
4.3 DRIVERS AND LIMITERS
4.3.1 Market Drivers
4.3.2 Market Limiters
4.4 COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
APPENDIX: COMPANY PRESS RELEASES
List of Charts
Chart 1 1: Interventional Cardiology Market by Segment, Japan, 2014 – 2024
Chart 1 2: Interventional Cardiology Market Overview, Japan, 2017 & 2024
Chart 9 1: Interventional Coronary Catheter Market, Japan, 2014 – 2024
Chart 9 2: Leading Competitors, Interventional Coronary Catheter Market, Japan, 2017
List of Figures
Figure 1 1: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (1 of 2)
Figure 1 2: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (2 of 2)
Figure 1 3: Companies Researched in this Report, Japan, 2017
Figure 1 4: Factors Impacting the Interventional Cardiology Market by Segment, Japan (1 of 2)
Figure 1 5: Factors Impacting the Interventional Cardiology Market by Segment, Japan (2 of 2)
Figure 1 6: Recent Events in the Interventional Cardiology Market, Japan, 2014 – 2017
Figure 1 7: Interventional Cardiology Markets Covered, Japan, 2017
Figure 1 8: Interventional Cardiology Procedures Covered, Japan, 2017
Figure 1 9: Version History
Figure 3 7: Coronary Catheters Products by Company (1 of 3)
Figure 3 8: Coronary Catheters Products by Company (2 of 3)
Figure 3 9: Coronary Catheters Products by Company (3 of 3)
Figure 3 10: Imaging Catheter Products by Company
Figure 3 20: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter
Figure 3 21: Class 2 Device Recall Boston Scientific, Small Peripheral Cutting BalloonTM
Figure 3 22: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM
Figure 3 23: Class 2 Device Recall Boston Scientific ACUITY Pro Coronary Sinus Guide Catheter
Figure 3 24: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter
Figure 3 25: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM
Figure 3 26: Class 1 Device Recall RotaWire Elite and sireClip Torquer, Guidewire and Guidewire Manipulation Device, Floppy
Figure 3 27: Class 2 Device Recall MynxGrip Vascular Closure Device
Figure 3 28: Class 2 Device Recall Zilver 518RX Vascular Stent
Figure 3 29: Class 2 Device Recall Zilver 518 Vascular Self Expanding Stent
Figure 3 30: Class 2 Device Recall White Lumax Guiding Coaxial Catheter
Figure 3 31: Class 2 Device Recall Cordis POWERFLEX PRO PTA Dilatation Catheter
Figure 3 32: Class 2 Device Recall EMPIRA (TM) NC RX PTCA Dilatation Catheter
Figure 3 33: Class 2 Device Recall Cordis EMPIRA RX PTCA Dilatation Catheter
Figure 3 34: Class 2 Device Recall Cordis ADROIT 6F Guiding Catheter
Figure 3 35: Class 2 Device Recall Resolute Integrity Zotarolimuseluting Coronary Stent
Figure 3 36: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter
Figure 3 37: Class 2 Device Recall Ev3, Inc. (Medtronic)
Figure 3 38: Class 2 Device Recall NC Sprinter; Rapid Exchange Balloon Dilatation Catheter
Figure 3 39: Class 2 Device Recall Medtronic Launcher Coronary Guide Catheter
Figure 3 40: Class 2 Device Recall Launcher Coronary Guiding Catheter
Figure 3 41: Class 1 Device Recall ZINGER Steerable Guidewire
Figure 3 42: Class 1 Device Recall Cougar Nitinol Workhorse Guidewire
Figure 3 43: Class 1 Device Recall COUGAR Steerable Guidewire
Figure 3 44: Class 1 Device Recall THUNDER Steerable Guidewire
Figure 3 45: Class 1 Device Recall ProVia CROSSING GUIDEWIRE
Figure 3 46: Class 1 Device Recall ATTAIN HYBRID Guide Wire
Figure 3 47: Class 2 Device Recall Medtronic Zuma Guide Catheter
Figure 3 48: Class 2 Device Recall Merit Maestro Microcatheter
Figure 3 49: Class 2 Device Recall Merit Laureate Hydrophilic Guide Wire
Figure 3 50: Class 2 Device Recall Maestro Microcatheter, Merit Medical System
Figure 3 51: Class 2 Device Recall Performa Cardiac Multipack Catheter
Figure 3 52: Class 2 Device Recall Hydrophylic guidewire
Figure 3 53: Class 2 Device Recall PreludeEASE
Figure 3 54: Class 2 Device Recall Prelude Pro Sheath Introducter
Figure 3 55: Class 2 Device Recall Turbo Elite Atherectomy Catheter
Figure 3 56: Class 2 Device Recall ELCA Coronary Atherectomy Catheter
Figure 3 57: Class 2 Device Recall Vascular closure device
Figure 3 58: Class 3 Device Recall FastCath Transseptal Guiding Introducer
Figure 3 59: Class 1 Device Recall TwinPass Dual Access Catheter
Figure 3 60: Class 2 Device Recall Percutaneous Catheter
Figure 3 61: Class 2 Device Recall Prestige Plus Wire
Figure 3 62: Class 2 Device Recall Volcano s5, s5i, CORE and CORE Mobile systems
Figure 3 63: Class 2 Device Recall Intravascular Ultrasound System
Figure 3 64: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular
Figure 3 65: Class 1 Device Recall LifeStent Solo Vascular Stent, Bard Peripheral Vascular
Figure 3 66: Class 2 Device Recall PTA Balloon Dilatation Catheters
Figure 3 67: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc.
Figure 3 68: Class 2 Device Recall Coronary Artery Perfusion Cannula with Balloon, Sorin Group USA, Inc.
Figure 3 69: Class 2 Device Recall Aortic Arch Cannula, Sorin Group USA, Inc.
Figure 3 70: Class 2 Device Recall Mallinckrodt Launcher Guiding Catheter, Stryker Sustainability Solutions
Figure 3 71: Class 2 Device Recall Distal Access Catheter (DAC), Concentric Medical Inc
Figure 3 72: Class 2 Device Recall Distal Access Catheter
Figure 3 73: Class 2 Device Recall Proplege Coronary Sinus Catheter, Edwards Lifesciences, LLC
Figure 3 74: Class 2 Device Recall Turbo Elite, ELCA Atherectomy Catheter, Spectranetics Corporation
Figure 3 75: Class 1 Device Recall Diamondback 360 Coronary Orbital Artherctomy System, Cardiovascular Systems, Inc.
Figure 3 76: Class 3 Device Recall Diamondback 360 Coronary Orbital Atherectomy System
Figure 3 77: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc
Figure 3 78: Class 1 Device Recall Halo One ThinWalled Guiding Sheath, Bard Peripheral Vascular
Figure 3 79: Class 2 Device Recall SOUNDSTAR eco Catheter, Biosense Webster, Inc.
Figure 3 80: XIENCE Xpedition/Alpine in Routine Clinical Practice (IRIS XPEDITION)
Figure 3 81: Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)
Figure 3 82: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ)
Figure 3 83: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE)
Figure 3 84: XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)
Figure 3 85: Absorb IV Randomized Controlled Trial
Figure 3 86: Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA)
Figure 3 87: Xience Versus Synergy in Left Main PCI (IDEAL-LM)
Figure 3 88: Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT)
Figure 3 89: XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS)
Figure 3 90: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS)
Figure 3 91: A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA)
Figure 3 92: AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN)
Figure 3 93: XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Figure 3 94: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent, Performance, and Technique in Chronic Total Occlusions
Figure 3 95: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE (PATRIOT)
Figure 3 96: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V)
Figure 3 97: Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE)
Figure 3 98: The Asahi Intecc PTCA Chronic Total Occlusion Study (CTO-PCI)
Figure 3 99: Optilene® Suture for Coronary Artery Bypass Graft Surgery (OPTICABG)
Figure 3 100: Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent
Figure 3 101: Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV)
Figure 3 102: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)
Figure 3 103: Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions (PEPCAD V)
Figure 3 104: The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations (PEPCAD-BIF)
Figure 3 105: INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent (INDICOR)
Figure 3 106: A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD)
Figure 3 107: The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO)
Figure 3 108: PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel
Figure 3 109: LEADERS FREE II: BioFreedom™ Pivotal Study
Figure 3 110: BioFreedom US IDE Feasibility Trial
Figure 3 111: A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free)
Figure 3 112: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease (ABSORB-LONG)
Figure 3 113: BIOTRONIK Orsiro Pre-Marketing Registration (BIOFLOW-VI)
Figure 3 114: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Figure 3 115: BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite
Figure 3 116: BIOHELIX-I Bare Metal Stent Study (BIOHELIX-I)
Figure 3 117: BIOFLOW III Asia Registry
Figure 3 118: BIOFLOW-III Israel Satellite Registry
Figure 3 119: Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT (REMEDEE-OCT)
Figure 3 120: Drug Eluting Pantera Lux Catheter Registry
Figure 3 121: Post-Approval Study of PROMUS Element™ in China (PEChina)
Figure 3 122: EVOLVE China Clinical Trial (EVOLVE China)
Figure 3 123: EVOLVE Short DAPT Study
Figure 3 124: PROMUS Element Plus US Post-Approval Study
Figure 3 125: The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
Figure 3 126: SYNERGY China: Assess SYNERGY Stent in China
Figure 3 127: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
Figure 3 128: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
Figure 3 129: Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions
Figure 3 130: RESOLUTE ONYX Post-Approval Study (ONYX PAS)
Figure 3 131: Medtronic RevElution Trial (RevElution)
Figure 3 132: The European Bifurcation Club Left Main Study (EBC MAIN)
Figure 3 133: Medtronic Resolute Onyx 2.0 mm Clinical Study
Figure 3 134: Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study
Figure 3 135: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
Figure 3 136: An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (RI-US)
Figure 3 137: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE)
Figure 3 138: Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP)
Figure 3 139: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT)
Figure 3 140: ILUMIEN III: OPTIMIZE PCI
Figure 3 141: ILUMIEN III: OPTIMIZE PCI
Figure 3 142: Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease (POST-IT)
Figure 3 143: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE)
Figure 3 144: Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis
Figure 3 145: Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s)
Figure 3 146: Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III)
Figure 3 147: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ)
Figure 3 148: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR)
Figure 3 149: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation
Figure 3 150: BIONICS - Pharmacokinetics (PK) Trial (BIONICS)
Figure 3 151: Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT II)
Figure 3 152: Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )
Figure 3 153: Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease (Firehawk_38)
Figure 3 154: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II)
Figure 3 155: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT)
Figure 3 156: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II), Reva Medical
Figure 3 157: Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I) (FANTOM I), Reva Medical
Figure 3 158: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
Figure 3 159: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus)
Figure 3 160: Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II)
Figure 3 161: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Figure 3 162: eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries (eTRYTONLM)
Figure 3 163: An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial (MeriT-II)
Figure 3 164: An BioMime Vs. Xience Randomised Control Clinical Study (meriT-V)
Figure 3 165: BIONICS Israel Trial
Figure 3 166: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System
Figure 3 167: Sapphire II PRO US Clinical Study
Figure 3 168: Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM)
Figure 3 169: Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I)
Figure 3 170: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation
Figure 3 171: Procedural Advantages of a Novel Drug-Eluting Coronary Stent
Figure 3 172: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
Figure 3 173: Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)
Figure 3 174: Drug Eluting Balloon for Prevention of Constrictive Remodeling
Figure 3 175: Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis
Figure 3 176: Real-time MRI Right Heart Catheterization Using Passive Catheters
Figure 3 177: A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions
Figure 3 178: Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI (RAPID)
Figure 3 179: A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter
Figure 3 180: Performance of the CARDIOGARD Cannula (GECG)
Figure 3 181: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR
Figure 3 182: Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft
Figure 3 183: Coherex WAVECREST I Left Atrial Appendage Occlusion Study
Figure 3 184: Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter
Figure 3 185: Prospective Randomized Optical Coherence Tomography Oslo tRial (PROCTOR)
Figure 3 186: Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation (OCTACS)
Figure 9 1: Interventional Coronary Catheter Market, Japan, 2014 – 2024
Figure 9 2: Drivers and Limiters, Interventional Coronary Catheter Market, Japan, 2017
Figure 9 3: Leading Competitors, Interventional Coronary Catheter Market, Japan, 2017
Figure 21 1: Press Release Summary

Japan Market Report for Interventional Coronary Catheters 2018 - MedCore

Interventional catheters are used by physicians in procedures for the placement of devices such as stents and balloons. There is a large variety of catheters, and their use depends on the size, shape and curvature of the lesion. Cardiologists tend to choose catheters based on their guidewire selection. Interventional catheters must be rigid without being stiff, because the device must adapt itself to the curvature of certain arteries. In addition, catheters must promptly react to a physician’s movements, sometimes following zigzag patterns, without risking puncturing the lumen.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;